Is the Metagenomi Therapeutics (MGX) investment thesis intact?

Yes. Readouts currently rates the Metagenomi Therapeutics Thesis Intact. Metagenomi aims to file the MGX-001 IND for hemophilia A by year-end.

What is the next catalyst for Metagenomi Therapeutics (MGX)?

The next dated event is IND submission for MGX-001, expected Q4 2026, as stated by the company.

How long will Metagenomi Therapeutics' cash last?

Metagenomi Therapeutics has said its cash will fund operations into Q4 2027 (guidance as of September 22, 2026). It reported $121 million in cash as of June 30, 2026.

MGXMetagenomi Therapeutics, Inc.

Market reactionShares rose 11% on Nov 3.

IntactLast material event Sep 22, 2026 · Updated Oct 25, 2026

Metagenomi aims to file the MGX-001 IND for hemophilia A by year-end

Metagenomi Therapeutics is a preclinical gene editing company developing MGX-001, a one-time treatment designed to insert a working factor VIII gene in people with hemophilia A.

Metagenomi's case rests on MGX-001, which uses an AAV vector and a CRISPR nuclease to insert a factor VIII gene at the albumin site in the liver. In monkeys it produced factor VIII in the normal range, and activity lasted about 19 months in an earlier study. No off-target edits were found at 623 candidate sites in human liver cells. Metagenomi plans to submit an IND in the fourth quarter of 2026 and dose the first patient in 2027. Cash was $120.7 million at June 30.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

The MGX-001 IND is filed and clearedAwaiting evidenceIND submission (fourth quarter of 2026).Next: IND submission (fourth quarter of 2026).

Why it is in this state

The evidence, what would weaken it and the source filing

The first patient is dosed in 2027Awaiting evidenceFirst patient dosed (2027).Next: First patient dosed (2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts until first human dataAt riskQ3 2026 cash balance.Next: Q3 2026 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

MGX-001 IND submission and clearance

Tests: The MGX-001 IND is filed and cleared

Fourth quarter of 2026

Does Metagenomi file the MGX-001 IND on time and receive clearance to dose patients?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

+1.8%Sep 22, 2026

Metagenomi aims to file the MGX-001 IND for hemophilia A by year-end

IntactRegulatory

-1.6%Aug 10, 2026

Curative NHP FVIII data fuels hemophilia A gene-editing bet, but human proof is still a 2027 question

IntactRegulatory

+5.9%May 11, 2026

MGX-001's hemophilia A bet hinges on whether preclinical FVIII durability translates to safe, curative editing in humans

IntactClinical

-15.4%Nov 12, 2025

MGX-001 carries curative NHP data into a 2026 IND; the thesis turns on clinical translation against established hemophilia A gene therapies

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Hemophilia A

MGX-001 · 2 upcoming · 1 completed

IND Submission

Q4 2026

Phase 1/2 Study Initiation

2027

Secreted protein deficiency

Secreted protein program · 1 completed

Data

Reported Jan 12, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Metagenomi Therapeutics (MGX) investment thesis intact?: Yes. Readouts currently rates the Metagenomi Therapeutics Thesis Intact. Metagenomi aims to file the MGX-001 IND for hemophilia A by year-end.
What is the next catalyst for Metagenomi Therapeutics (MGX)?: The next dated event is IND submission for MGX-001, expected Q4 2026, as stated by the company.
How long will Metagenomi Therapeutics' cash last?: Metagenomi Therapeutics has said its cash will fund operations into Q4 2027 (guidance as of September 22, 2026). It reported $121 million in cash as of June 30, 2026.

Disease areas: Blood disorders, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

vs. direct competitors

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.